source
- MassBio and SCbio select 10 life science startups for Drive acceleratorMassBio and SCbio announced that ten early‑stage life‑science companies have been chosen for the fall cohorts of the Drive accelerator program. The selection includes five biotech firms and five te…
- Ultragenyx’s Angelman therapy fails Phase 3, stock drops over 43% and company announces strategic reviewUltragenyx reported that its investigational Angelman syndrome drug apazunersen did not meet the primary cognitive endpoints in a Phase 3 trial. The lack of efficacy means the therapy will not prov…